The estimated Net Worth of David B Seaburg is at least $589 Thousand dollars as of 19 October 2021. David Seaburg owns over 31,037 units of PolarityTE Inc stock worth over $321,416 and over the last 6 years David sold PTE stock worth over $267,352.
David has made over 15 trades of the PolarityTE Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently David sold 31,037 units of PTE stock worth $17,070 on 19 October 2021.
The largest trade David's ever made was buying 35,000 units of PolarityTE Inc stock on 5 June 2019 worth over $207,550. On average, David trades about 9,198 units every 26 days since 2018. As of 19 October 2021 David still owns at least 1,339,232 units of PolarityTE Inc stock.
You can see the complete history of David Seaburg stock trades at the bottom of the page.
David's mailing address filed with the SEC is 170 E 78th St, New York, NY 10075, USA.
Over the last 6 years, insiders at PolarityTE Inc have traded over $998,958 worth of PolarityTE Inc stock and bought 381,180 units worth $1,230,731 . The most active insiders traders include Steve Gorlin, Peter A Cohen, and Paul Elliot Mann. On average, PolarityTE Inc executives and independent directors trade stock every 21 days with the average trade being worth of $3,753. The most recent stock trade was executed by Chris Nolet on 12 January 2023, trading 36,497 units of PTE stock currently worth $8,759.
polarityte, inc. (nasdaq: cool) is the owner of a novel regenerative medicine and tissue engineering platform developed and patented by denver lough md, phd. this radical and proprietary technology employs a patients' own cells for the healing of full-thickness functionally-polarized tissues. if clinically successful, the polarityte platform will be able to provide medical professionals with a truly new paradigm in wound healing and reconstructive surgery by utilizing a patient's own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. it is because polarityte uses a natural and biologically sound platform technology, which is readily adaptable to a wide spectrum of organ and tissue systems, that the company and its world-renowned clinical advisory board, are poised to drastically change the field and future of translational regenerative medicine. more info can be found online at www.polarityte.com welcome to the shift™
PolarityTE Inc executives and other stock owners filed with the SEC include: